Avi Biopharma Inc - Current report filing (8-K)
December 05 2007 - 3:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 3,
2007
AVI
BioPharma, Inc.
(Exact name of Company as specified in its charter)
Oregon
|
|
0-22613
|
|
93-0797222
|
(State or other
|
|
(Commission File
No.)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification
No.)
|
incorporation)
|
|
|
|
|
One
S.W. Columbia, Suite 1105
Portland,
OR 97258
(Address of principal executive offices)
(503)
227-0554
Registrants telephone number, including area code
Not
Applicable
(Former name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other Events.
On December 3, 2007, AVI BioPharma, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track status to its product candidate, AVI-4658, for the treatment of Duchenne Muscular Dystrophy (DMD). The text of the press release is included as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01 Financial
Statements and Exhibits.
(d)
Exhibits
The following
exhibits are filed herewith:
Exhibit 99.1
Press Release
dated December 3, 2007 announcing Fast Track Status for
AVI-4658
2
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act
of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, in the City of
Portland, State of Oregon, on December 5, 2007.
|
AVI
BioPharma, Inc.
|
|
|
|
|
By:
|
/s/ ALAN P.
TIMMINS
|
|
|
|
|
|
Alan P. Timmins
|
|
|
President
and Chief Operating Officer
(Principal
Operating Officer)
|
3
Exhibit Index
Exhibit
|
|
Description
|
99.1
|
|
Press Release dated
December 3, 2007 announcing Fast Track Status for AVI-4658
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024